一种来源于牛初乳粉消化产物的降血糖活性肽及其应用
CN122404479APending Publication Date: 2026-07-17HANGZHOU CHAOMU ELECTRONIC COMMERCE CO LTD +2
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- HANGZHOU CHAOMU ELECTRONIC COMMERCE CO LTD
- Filing Date
- 2026-06-17
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Current methods of blood glucose regulation mostly rely on drug treatment, which has side effects and cannot meet people's demand for natural and safe methods. Dipeptidyl peptidase IV (DPP-IV) rapidly hydrolyzes GLP-1 and GIP, leading to blood glucose inactivation.
Method used
A hypoglycemic active peptide derived from bovine colostrum powder was developed. The amino acid sequence is DMLP, which has significant DPP-IV inhibitory activity and can be used to prepare hypoglycemic products.
Benefits of technology
It significantly inhibits DPP-IV activity, increases the levels of GLP-1 and GIP in vivo, promotes insulin secretion, effectively regulates blood glucose homeostasis, has high safety, is suitable for long-term consumption, and has broad market application prospects.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122404479A_ABST
Abstract
本申请公开一种来源于牛初乳粉消化产物的降血糖活性肽及其应用，降血糖活性肽的氨基酸序列为DMLP，该活性肽来源于母牛产犊后24h内的牛初乳，经验证，该从牛初乳中得到的活性肽具有显著的DPP‑IV抑制活性。本申请的活性肽来源于牛初乳，安全性高，生物相容性好，相较于化学合成药物，更适合长期食用或使用，可用于制备多种类型的降血糖相关产品，满足不同人群的需求，市场应用前景广阔。
Need to check novelty before this filing date? Find Prior Art